{"id":"folfiri-cetuximab","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"80-90","effect":"Acneiform rash"},{"rate":"30-40","effect":"Anemia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFIRI is a combination chemotherapy regimen (fluorouracil, leucovorin, and irinotecan) that damages DNA in dividing cells. Cetuximab is a monoclonal antibody that binds to EGFR on cancer cell surfaces, blocking growth signals and enhancing the cytotoxic effects of chemotherapy. This combination is particularly effective in colorectal cancers that express EGFR and are wild-type for KRAS.","oneSentence":"FOLFIRI chemotherapy combined with cetuximab targets rapidly dividing cancer cells and blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:42.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer, KRAS wild-type"},{"name":"Locally advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT06179160","phase":"PHASE1","title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-01-04","conditions":"Solid Tumors","enrollment":710},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":"Dynamic Tumor Resistance, Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT03803553","phase":"PHASE3","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-04-16","conditions":"Metastatic Colon Cancer, Stage III Colon Cancer","enrollment":400},{"nctId":"NCT05836324","phase":"PHASE1","title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-07-24","conditions":"Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":408},{"nctId":"NCT07253896","phase":"PHASE2","title":"Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-03","conditions":"Safety","enrollment":40},{"nctId":"NCT05786924","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2023-04-18","conditions":"Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis","enrollment":554},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT04776655","phase":"PHASE3","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-30","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation","enrollment":280},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT06279351","phase":"PHASE2","title":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2024-08-11","conditions":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","enrollment":96},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT04554836","phase":"PHASE2","title":"MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab","status":"COMPLETED","sponsor":"TheraOp","startDate":"2020-12-29","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum","enrollment":6},{"nctId":"NCT07004413","phase":"PHASE3","title":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-01-01","conditions":"Colorectal Cancer Metastatic","enrollment":267},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT06959589","phase":"PHASE2","title":"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-06-01","conditions":"Colorectal Cancer Metastatic, KRAS G12C Mutation","enrollment":50},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT05217069","phase":"PHASE2","title":"FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2019-09-27","conditions":"Treatment Related Cancer","enrollment":57},{"nctId":"NCT05004350","phase":"PHASE2","title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-14","conditions":"BRAF V600E, Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT06833866","phase":"PHASE1","title":"Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-04","conditions":"Advanced or Metastatic CRC","enrollment":33},{"nctId":"NCT06640166","phase":"PHASE2","title":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-06-03","conditions":"Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor","enrollment":25},{"nctId":"NCT04793958","phase":"PHASE3","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-24","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":461},{"nctId":"NCT01878422","phase":"PHASE3","title":"Sequential Treatment Strategy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":376},{"nctId":"NCT06776757","phase":"PHASE1, PHASE2","title":"Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2023-12-25","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT05894694","phase":"PHASE4","title":"Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2023-09-27","conditions":"Advanced Colorectal Carcinoma","enrollment":320},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT03874026","phase":"PHASE2","title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2019-09-05","conditions":"Colorectal Cancer, ADCC","enrollment":34},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT06590259","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-03-12","conditions":"Colorectal Cancer Liver Metastasis","enrollment":20},{"nctId":"NCT06603376","phase":"PHASE2","title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-09-01","conditions":"Colorectal Carcinoma","enrollment":75},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT06322147","phase":"","title":"Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-06-01","conditions":"Colon Cancer","enrollment":50},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT06231017","phase":"PHASE2","title":"Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-19","conditions":"Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT03135652","phase":"PHASE2","title":"Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation","status":"WITHDRAWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2017-08-01","conditions":"Radiotherapy, Colorectal Cancer, Liver Metastases","enrollment":""},{"nctId":"NCT02928224","phase":"PHASE3","title":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-13","conditions":"BRAF V600E-mutant Metastatic Colorectal Cancer","enrollment":702},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT03391934","phase":"PHASE3","title":"Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2018-01-20","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT05684211","phase":"PHASE2","title":"A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Shanghai Celfuture Biotech Co., Ltd.","startDate":"2023-01","conditions":"Colorectal Cancer","enrollment":84},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT01326000","phase":"PHASE2","title":"A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04","conditions":"Colorectal Cancer","enrollment":169},{"nctId":"NCT02404935","phase":"PHASE2","title":"Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2013-11-22","conditions":"Metastatic Colorectal Cancer","enrollment":139},{"nctId":"NCT01442649","phase":"PHASE2","title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":133},{"nctId":"NCT05103020","phase":"PHASE2","title":"Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-11-01","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT03727763","phase":"PHASE2","title":"Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2018-10-08","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT01276379","phase":"PHASE2","title":"Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2011-01","conditions":"Colorectal Cancer","enrollment":221},{"nctId":"NCT01442935","phase":"PHASE2","title":"Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-02","conditions":"Colorectal Cancer","enrollment":256},{"nctId":"NCT01345526","phase":"PHASE2","title":"Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream","status":"COMPLETED","sponsor":"Universitätsmedizin Mannheim","startDate":"2011-04","conditions":"Metastatic Colorectal Cancer","enrollment":124},{"nctId":"NCT02942706","phase":"PHASE2, PHASE3","title":"Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-11","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT03286738","phase":"","title":"Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Joong Bae Ahn","startDate":"2015-11","conditions":"Metastatic Colorectal Cancer","enrollment":1800},{"nctId":"NCT04831528","phase":"","title":"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-04-10","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT02624895","phase":"","title":"ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-12-30","conditions":"Metastatic Colorectal Cancer","enrollment":296},{"nctId":"NCT04718038","phase":"","title":"Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2016-07-01","conditions":"Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT01394939","phase":"PHASE1, PHASE2","title":"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2012-01","conditions":"Colorectal Carcinoma, CRC","enrollment":52},{"nctId":"NCT01703390","phase":"PHASE2","title":"Biomarker Directed Treatment in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2012-12-04","conditions":"Metastatic Colorectal Cancer","enrollment":47},{"nctId":"NCT01867697","phase":"PHASE2","title":"Nordic 8 - A Phase II Trial","status":"COMPLETED","sponsor":"Per Pfeiffer","startDate":"2012-05","conditions":"Metastatic Colorectal Cancer","enrollment":173},{"nctId":"NCT04525326","phase":"PHASE3","title":"Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-10-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":584},{"nctId":"NCT01832467","phase":"PHASE2","title":"Cetuximab Rechallenge Study","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2013-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":17},{"nctId":"NCT00265850","phase":"PHASE3","title":"Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2005-11","conditions":"Colorectal Cancer","enrollment":2334},{"nctId":"NCT02484833","phase":"PHASE3","title":"Erbitux MEtastatic Colorectal Cancer Strategy Study","status":"COMPLETED","sponsor":"Armando Orlandi","startDate":"2015-02","conditions":"Antineoplastic Agents","enrollment":607},{"nctId":"NCT01317433","phase":"NA","title":"Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2010-12-29","conditions":"Colorectal Cancer Metastatic, Skin Toxicity","enrollment":25},{"nctId":"NCT03688230","phase":"PHASE2","title":"Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.","status":"WITHDRAWN","sponsor":"SFJ Pharmaceuticals X, LTD.","startDate":"2019-04","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03323424","phase":"PHASE2","title":"Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers","status":"WITHDRAWN","sponsor":"Institut de Cancérologie de la Loire","startDate":"2019-01-01","conditions":"Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer","enrollment":""},{"nctId":"NCT03022734","phase":"PHASE2","title":"Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-09","conditions":"Rectal Cancer, Metastatic","enrollment":40},{"nctId":"NCT01251536","phase":"PHASE2","title":"Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":108},{"nctId":"NCT01923987","phase":"PHASE2","title":"Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-08","conditions":"Rectal Cancer, Liver Metastasis, Lung Metastasis","enrollment":39},{"nctId":"NCT01802645","phase":"PHASE2","title":"Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2013-03","conditions":"Colorectal Cancer","enrollment":91},{"nctId":"NCT01640444","phase":"PHASE2","title":"Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2012-07","conditions":"Colorectal Cancer Metastatic","enrollment":240},{"nctId":"NCT01523639","phase":"PHASE2","title":"A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis","status":"TERMINATED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2012-04","conditions":"Colorectal Cancer, Steatohepatitis","enrollment":8},{"nctId":"NCT01540344","phase":"PHASE2","title":"Combined Anticancer Treatment of Advanced Colon Cancer","status":"TERMINATED","sponsor":"University of Regensburg","startDate":"2010-10","conditions":"Peritoneal Carcinomatosis, Colorectal Cancer Metastatic","enrollment":26},{"nctId":"NCT00954512","phase":"PHASE1, PHASE2","title":"Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Neoplasms","enrollment":15},{"nctId":"NCT00551213","phase":"PHASE2","title":"A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-21","conditions":"Colorectal Cancer","enrollment":67},{"nctId":"NCT02508077","phase":"PHASE2","title":"FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2016-02-16","conditions":"Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer","enrollment":1},{"nctId":"NCT00577109","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00077233","phase":"PHASE3","title":"FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-12","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT01472016","phase":"PHASE1","title":"Study of ABT-700 in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10-06","conditions":"Advanced Solid Tumors","enrollment":74},{"nctId":"NCT02316496","phase":"PHASE2","title":"Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study","status":"TERMINATED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2015-09-23","conditions":"Colorectal Cancer Metastatic","enrollment":2},{"nctId":"NCT01134666","phase":"","title":"An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-11-30","conditions":"Colorectal Neoplasms","enrollment":165},{"nctId":"NCT00497497","phase":"PHASE1","title":"A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-10","conditions":"Colorectal Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLADDER INJURY"},{"count":1,"reaction":"COLORECTAL CANCER METASTATIC"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"DYSPHONIA"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"HYDRONEPHROSIS"},{"count":1,"reaction":"METASTASES TO ABDOMINAL CAVITY"},{"count":1,"reaction":"METASTASES TO BONE"},{"count":1,"reaction":"METASTASES TO LIVER"},{"count":1,"reaction":"METASTASES TO LUNG"}],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FOLFIRI + cetuximab","genericName":"FOLFIRI + cetuximab","companyName":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","companyId":"spanish-cooperative-group-for-the-treatment-of-digestive-tumours-ttd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRI is a chemotherapy regimen used to treat various conditions, including metastatic colorectal cancer. Cetuximab, an epidermal growth factor receptor inhibitor, is often combined with FOLFIRI as a treatment for advanced colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}